MSD has started a phase 3 trial of ROR1-directed zilovertamab vedotin (zilo-V) as a treatment for previously untreated diffuse large B-cell lymphoma (DLBCL), cementing the antibody-drug conjugate's ...
MSD began worldwide recruitment for the trial and subjects are currently being enrolled. In the randomised trial, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback